Physician profile
Ryan Bruce Corcoran
NPI 1508993957
$254,567.84
in general payments reported to CMS, 2019-2025
19 companies · $58K in 2025
The $58K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $43K · 2021: $41K · 2022: $20K · 2023: $33K · 2024: $26K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $101K · Travel and Lodging: $15K · Food and Beverage: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $101,150.00 |
| Travel and Lodging | $15,310.15 |
| Food and Beverage | $668.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qiagen, LLC | $108,000.00 | 2020-2025 | |
| Taiho Oncology, INC. | $54,459.72 | 2019-2025 | |
| Abbvie INC. | $27,361.55 | 2020-2025 | |
| Array Biopharma INC | $18,161.57 | 2019-2022 | |
| Ipsen Bioscience INC. | $11,496.25 | 2020-2021 | |
| F. Hoffmann-La Roche Ag | $8,391.75 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $4,957.82 | 2019-2021 | |
| Pfizer INC. | $4,284.89 | 2020 | |
| Amgen INC. | $3,430.00 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $3,239.51 | 2019-2025 | |
| Daiichi Sankyo INC. | $2,205.00 | 2023 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $1,500.00 | 2019 | |
| Merck Sharp & Dohme LLC | $1,500.00 | 2021 | |
| Shionogi INC | $1,370.00 | 2019 | |
| Astellas Pharma INC | $1,278.60 | 2022-2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $1,140.00 | 2025 | Tecentriq |
| Mirati Therapeutics, INC. | $1,078.76 | 2023 | Krazati |
| Otsuka Pharmaceutical Co., LTD. | $712.42 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Corcoran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.